Салухов В.В., Харитонов М.А. (ред.). Практическая пульмонология. М.: ГЭОТАР-Медиа; 2017. 416 с.
Dechant K.L., Noble S. Erdosteine. Drugs. 1996;52(6):875–881. https://doi.org/10.2165/00003495-199652060-00009..
DOI: 10.2165/00003495-199652060-00009
Cazzola M., Calzetta L., Page C., Rogliani P., Matera M.G. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends Pharmacol Sci. 2019;40(7):452–463. https://doi.org/10.1016/j.tips.2019.04.015..
DOI: 10.1016/j.tips.2019.04.015
Miyake K., Kaise T., Hosoe H., Akuta K., Manabe H., Ohmori K. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflamm Res. 1999;48(4):205–209. https://doi.org/10.1007/s000110050447..
DOI: 10.1007/s000110050447
Hosoe H., Kaise T., Ohmori K., Isohama Y., Kai H., Takahama K., Miyata T. Mucolytic and antitussive effects of erdosteine. J Pharm Pharmacol. 1999;51(8):959–966. https://doi.org/10.1211/0022357991773230..
DOI: 10.1211/0022357991773230
Hattori M. Mucociliary function of chronic inflammation in upper and lower airways. Auris Nasus Larynx. 1994;21(4):219–225. https://doi.org/10.1016/S0385-8146(12)80084-8..
DOI: 10.1016/S0385-8146(12)80084-8
Braga P.C., Dal Sasso M., Zuccotti T. Assessment of the antioxidant activity of the SH metabolite I of erdosteine on human neutrophil oxidative bursts. Arzneimittelforschung. 2000;50(8):739–746. https://doi.org/10.1055/s-0031-1300281..
DOI: 10.1055/s-0031-1300281
Marabini L., Calò R., Braga P.C. Protective effect of erdosteine metabolite I against hydrogen peroxide-induced oxidative DNA-damage in lung epithelial cells. Arzneimittelforschung. 2011;61(12):700–706. https://doi.org/10.1055/s-0031-1300590..
DOI: 10.1055/s-0031-1300590
Braga P.C., Culici M., Dal Sasso M., Falchi M., Spallino A. Free radical scavenging activity of erdosteine metabolite I investigated by electron paramagnetic resonance spectroscopy. Pharmacol. 2010;85(4):195–202. https://doi.org/10.1159/000275063..
DOI: 10.1159/000275063
Boyaci H., Maral H., Turan G., Başyiğit I., Dillioğlugil M.O., Yildiz F. et al. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem. 2006;281(1–2):129–137. https://doi.org/10.1007/s11010-006-0640-3..
DOI: 10.1007/s11010-006-0640-3
Jang Y.Y., Song J.H., Shin Y.K., Han E.S., Lee C.S. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol Toxicol. 2003;92(4):173–179. https://doi.org/10.1034/j.1600-0773.2003.920407.x..
DOI: 10.1034/j.1600-0773.2003.920407.x
Cazzola M., Page C., Rogliani P., Calzetta L., Matera M.G. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs. 2020;80(17):1799–1809. https://doi.org/10.1007/s40265-020-01412-x..
DOI: 10.1007/s40265-020-01412-x
Braga PC., Dal Sasso M., Sala M.T., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999;49(4):344–350. https://doi.org/10.1055/s-0031-1300425..
DOI: 10.1055/s-0031-1300425
Braga P.C., Zuccotti T., Dal Sasso M. Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy. 2001;47(3):208–214. https://doi.org/10.1159/000063223..
DOI: 10.1159/000063223
Dal S.M., Bovio C., Culici M., Braga P.C. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res. 2002;28(2–3):75–82. Available at: https://pubmed.ncbi.nlm.nih.gov/12224380.https://pubmed.ncbi.nlm.nih.gov/12224380
Dal S.M., Bovio C., Culici M., Braga P.C. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exp Clin Res. 2002;28(2–3):75–82. Available at: https://pubmed.ncbi.nlm.nih.gov/12224380.https://pubmed.ncbi.nlm.nih.gov/12224380
Ricevuti G., Mazzone A., Uccelli E., Gazzani G., Fregnan G.B. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax. 1988;43(8):585–590. https://doi.org/10.1136/thx.43.8.585..
DOI: 10.1136/thx.43.8.585
Marchioni C.F., Polu J.M., Taytard A., Hanard T., Noseda G., Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther. 1995;33(11):612–618. Available at: https://pubmed.ncbi.nlm.nih.gov/8688986.https://pubmed.ncbi.nlm.nih.gov/8688986
Marchioni C.F., Polu J.M., Taytard A., Hanard T., Noseda G., Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther. 1995;33(11):612–618. Available at: https://pubmed.ncbi.nlm.nih.gov/8688986.https://pubmed.ncbi.nlm.nih.gov/8688986
Saggers B.A., Lawson D. Some observations on the penetration of antibiotics through mucus in vitro. J Clin Pathol. 1966;19(4):313–317. https://doi.org/10.1136/jcp.19.4.313..
DOI: 10.1136/jcp.19.4.313
Goswami M., Jawali N. N-acetylcysteine-mediated modulation of bacterial antibiotic susceptibility. Antimicrob Agents Chemother. 2010;54(8):3529–3530. https://doi.org/10.1128/aac.00710-10..
DOI: 10.1128/aac.00710-10
Landini G., Di Maggio T., Sergio F., Docquier J.D., Rossolini G.M., Pallecchi L. Effect of High N-Acetylcysteine Concentrations on Antibiotic Activity against a Large Collection of Respiratory Pathogens. Antimicrob Agents Chemother. 2016;60(12):7513–7517. https://doi.org/10.1128/aac.01334-16..
DOI: 10.1128/aac.01334-16
Irwin R.S., Boulet L.P., Cloutier M.M., Fuller R., Gold P.M., Hoffstein V et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest. 1998;114(Suppl. 2): 133S–181S. https://doi.org/10.1378/chest.114.2_supplement.133s..
DOI: 10.1378/chest.114.2_supplement.133s
Aubier M., Berdah L. Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion. Rev Mal Respir. 1999;16(4):521–528. Available at: https://pubmed.ncbi.nlm.nih.gov/10549062.https://pubmed.ncbi.nlm.nih.gov/10549062
Aubier M., Berdah L. Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion. Rev Mal Respir. 1999;16(4):521–528. Available at: https://pubmed.ncbi.nlm.nih.gov/10549062.https://pubmed.ncbi.nlm.nih.gov/10549062
Moretti M., Bottrighi P., Dallari R., Da Porto R., Dolcetti A., Grandi P. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004;30(4):143–152. Available at: https://pubmed.ncbi.nlm.nih.gov/15553660.https://pubmed.ncbi.nlm.nih.gov/15553660
Moretti M., Bottrighi P., Dallari R., Da Porto R., Dolcetti A., Grandi P. et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004;30(4):143–152. Available at: https://pubmed.ncbi.nlm.nih.gov/15553660.https://pubmed.ncbi.nlm.nih.gov/15553660
Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008;21(2):304–308. https://doi.org/10.1016/j.pupt.2007.07.004..
DOI: 10.1016/j.pupt.2007.07.004
Dal Negro R.W., Wedzicha J.A., Iversen M., Fontana G., Page C., Cicero A.F. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50(4):1700–1711. https://doi.org/10.1183/13993003.00711-2017..
DOI: 10.1183/13993003.00711-2017
Calverley P.M., Page C., Dal Negro R.W., Fontana G., Cazzola M., Cicero A.F. et al. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation. Int J Chron Obstruct Pulmon Dis. 2019;2019:2733–2744. https://doi.org/10.2147/COPD.S221852..
DOI: 10.2147/COPD.S221852
Rogliani P., Matera M.G., Page C., Puxeddu E., Cazzola M., Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019;20(1):104. https://doi.org/10.1186/s12931-019-1078-y..
DOI: 10.1186/s12931-019-1078-y
Kopriva F., Latalova V. Improving the Primary Care Management of Preschool Children with Recurrent Acute Respiratory Tract Infections in the Czech Republic: Prompt Use of Erdosteine Can Reduce Antibiotic Prescribing. Qual Prim Care. 2019;27(4):36–42. Available at: https://www.primescholars.com/articles/improving-the-primary-care-management-of-preschool-children-withrecurrent-acute-respiratory-tract-infections-in-the-czech-republi.pdf.https://www.primescholars.com/articles/improving-the-primary-care-management-of-preschool-children-withrecurrent-acute-respiratory-tract-infections-in-the-czech-republi.pdf
Kopriva F., Latalova V. Improving the Primary Care Management of Preschool Children with Recurrent Acute Respiratory Tract Infections in the Czech Republic: Prompt Use of Erdosteine Can Reduce Antibiotic Prescribing. Qual Prim Care. 2019;27(4):36–42. Available at: https://www.primescholars.com/articles/improving-the-primary-care-management-of-preschool-children-withrecurrent-acute-respiratory-tract-infections-in-the-czech-republi.pdf.https://www.primescholars.com/articles/improving-the-primary-care-management-of-preschool-children-withrecurrent-acute-respiratory-tract-infections-in-the-czech-republi.pdf
Balli F., Bergamini B., Calistru P., Ciofu E.P., Domenici R., Doros G. et al. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children. Int J Clin Pharmacol Ther. 2007;45(1):16–22. https://doi.org/10.5414/cpp45016..
DOI: 10.5414/cpp45016
Hötzinger H. Erdosteine or placebo combined with co-trimoxazole in the treatment of hypersecretive infectious bronchitis: A double blind clinical trial. Med Praxis. 1991;12:171–181.
Салухов В.В., Харитонов М.А., Николаев А.В., Зайцев А.А., Казанцев В.А., Иванов В.В. и др. Острый бронхит: от понимания этиологии к адекватной терапии. Вестник Российской Военно-медицинской академии. 2019;(1):206–213. Режим доступа: https://www.elibrary.ru/item.asp?ysclid=l8xbld9f9s814791037&id=37141871.https://www.elibrary.ru/item.asp?ysclid=l8xbld9f9s814791037&id=37141871
Салухов В.В., Харитонов М.А., Николаев А.В., Зайцев А.А., Казанцев В.А., Иванов В.В. и др. Острый бронхит: от понимания этиологии к адекватной терапии. Вестник Российской Военно-медицинской академии. 2019;(1):206–213. Режим доступа: https://www.elibrary.ru/item.asp?ysclid=l8xbld9f9s814791037&id=37141871.https://www.elibrary.ru/item.asp?ysclid=l8xbld9f9s814791037&id=37141871
Santus P., Tursi F., Croce G., Di Simone C., Frassanito F., Gaboardi P. et al. Changes in quality of life and dyspnoea after hospitalization in COVID-19 patients discharged at home. Multidiscip Respir Med. 2020;15(1):713. https://doi.org/10.4081/mrm.2020.713..
DOI: 10.4081/mrm.2020.713
Fraňová S., Kazimierová I., Pappová L., Molitorisová M., Jošková M., Šutovská M. The effect of erdosteine on airway defence mechanisms and inflammatory cytokines in the settings of allergic inflammation. Pulm Pharmacol Ther. 2019;54:60–67. https://doi.org/10.1016/j.pupt.2018.11.006..
DOI: 10.1016/j.pupt.2018.11.006
Салухов В.В., Харитонов М.А., Крюков Е.В., Степанова Т.В., Николаев А.В., Рудаков Ю.В. и др. Актуальные вопросы диагностики, обследования и лечения больных с COVID-19-ассоциированной пневмонией в различных странах и континентах. Медицинский совет. 2020;(21):96–102. https://doi.org/10.21518/2079-701X-2020-21-96-102..
DOI: 10.21518/2079-701X-2020-21-96-102
Iciek M., Bilska-Wilkosz A., Kozdrowicki M., Górny M. Reactive Sulfur Compounds in the Fight against COVID-19. Antioxidants (Basel). 2022;11(6):1053. https://doi.org/10.3390/antiox11061053..
DOI: 10.3390/antiox11061053
Yildirim Z., Kotuk M., Iraz M., Kuku I., Ulu R., Armutcu F., Ozen S. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine. Pulm Pharmacol Ther. 2005;18(5):367–373. https://doi.org/10.1016/j.pupt.2005.02.001..
DOI: 10.1016/j.pupt.2005.02.001